MetLife (MET) Q3 2026 Earnings Call Transcript

MetLife reported third-quarter adjusted EPS of $2.85 excluding notable items, up 22% year over year and a quarterly record; adjusted ROE was 19.6%, above its 15%–17% full-year target range. Adjusted earnings rose 17% to $1.8 billion, supported by investment income, volume growth and favorable underwriting, while $720 million of pretax variable investment income exceeded the implied $400 million quarterly run rate. The company repurchased $650 million of shares in the quarter and another $265 million in October; management said it remains on track to beat its 12.1% full-year expense-ratio target, while flagging seasonal mortality and disability-claim trends as risks.

Analysis

MET: Strong operating base, noisy incremental earnings

The key distinction is between durable execution and a favorable investment-income quarter. Above-normal variable investment income boosts reported upside but is not a sound basis for annualizing EPS; the net-income uplift from rate-driven accounting marks is even less informative about distributable earnings. The more investable signal is whether expense productivity, new-business returns and capital-light mix keep supporting per-share growth after those items normalize.

Near term, seasonal mortality and elevated disability claims make Group Benefits’ unusually favorable underwriting vulnerable to sequential giveback. Over 1–3 months, watch whether core RIS spread remains near its stated range as variable investment income normalizes, and whether the lumpy U.S. pension-transfer pipeline converts. Over 6–18 months, the thesis depends on disciplined capital deployment and PineBridge translating added assets into profitable mandates—not AUM growth alone. Public fixed-income outflows and rate-related AUM marks are a reminder that scale does not guarantee fee growth.

The contrarian point: the quarter’s headline beat may overstate the change in run-rate, but the market may also underweight capital efficiency and the option value of diversified retirement channels. AI-linked credit exposure is small relative to the general account, so it is not the central thesis; monitor long-dated hyperscaler exposure for spread or credit deterioration rather than treating AI exposure as automatic upside. Valuation and current market reaction are not supplied, so avoid assuming the beat is mispriced.

Key Decisions for Investors

• Do not chase a premarket gap on headline EPS. Consider a staged long in MET on post-earnings weakness, conditional on core RIS spread staying within management’s range and expense guidance remaining intact; without valuation and price data, no price target or fixed upside/downside estimate is justified.
• For a 1–3 month catalyst check, track Q4 variable investment income against the company’s stated normal run rate, U.S. pension-transfer execution, and Group Benefits claims. Favorable mortality should not be extrapolated; normal flu seasonality and a gradual multi-year underwriting normalization are credible offsets.
• Keep the longer-term long thesis only while value of new business returns and payback remain near recent levels and buybacks do not crowd out higher-return organic opportunities. Reassess if guidance is cut, core spread falls below the stated range, or disability claims push the nonmedical health ratio persistently above its target band.
• Treat AI infrastructure exposure as a credit-monitoring item, not a thematic re-rating catalyst. Watch data-center refinancing conditions and credit spreads; impairments, delinquencies, or material underwriting deterioration would challenge the balance-sheet comfort case.